KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Deferred Taxes (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Deferred Taxes for 10 consecutive years, with $19.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Deferred Taxes rose 26493.06% to $19.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.2 million, a 125.85% increase, with the full-year FY2025 number at $5.2 million, up 125.85% from a year prior.
  • Deferred Taxes was $19.0 million for Q4 2025 at Supernus Pharmaceuticals, up from -$2.6 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $19.0 million in Q4 2025 to a low of -$13.0 million in Q1 2022.
  • A 5-year average of -$3.6 million and a median of -$4.3 million in 2021 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: crashed 1160.23% in 2024, then soared 26493.06% in 2025.
  • Supernus Pharmaceuticals' Deferred Taxes stood at -$4.5 million in 2021, then crashed by 71.87% to -$7.8 million in 2022, then crashed by 34.78% to -$10.5 million in 2023, then surged by 99.31% to -$72000.0 in 2024, then skyrocketed by 26493.06% to $19.0 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Deferred Taxes are $19.0 million (Q4 2025), -$2.6 million (Q3 2025), and -$7.2 million (Q2 2025).